RAP1A and BRAF

Number of citations of the paper that reports this interaction (PubMedID 9560161)
199

Data Source:
BioGRID (affinity chromatography technology)
HPRD (in vivo)

		RAP1A	BRAF
Description		RAP1A, member of RAS oncogene family	B-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Cytoplasm Early Endosome Late Endosome Cytosol Plasma Membrane Cell Junction Guanyl-nucleotide Exchange Factor Complex Specific Granule Membrane Neuron Projection Phagocytic Vesicle Perinuclear Region Of Cytoplasm Extracellular Exosome Glutamatergic Synapse	Nucleus Mitochondrion Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle
	Molecular Function	GTPase Activity Protein Binding GTP Binding Rap Guanyl-nucleotide Exchange Factor Activity GDP Binding Protein-containing Complex Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding
	Biological Process	Response To Carbohydrate Positive Regulation Of Neuron Projection Development Microvillus Assembly Rap Protein Signal Transduction Negative Regulation Of Collagen Biosynthetic Process Cellular Response To Drug Nerve Growth Factor Signaling Pathway Neutrophil Degranulation Positive Regulation Of GTPase Activity Positive Regulation Of Protein Kinase Activity Positive Regulation Of Glucose Import Regulation Of Insulin Secretion Establishment Of Endothelial Barrier Positive Regulation Of ERK1 And ERK2 Cascade Cellular Response To CAMP Protein Localization To Plasma Membrane Response To Antineoplastic Agent Liver Regeneration Regulation Of Neurotransmitter Receptor Localization To Postsynaptic Specialization Membrane Regulation Of Cell Junction Assembly Positive Regulation Of Fc-gamma Receptor Signaling Pathway Involved In Phagocytosis Cellular Response To Nerve Growth Factor Stimulus Negative Regulation Of Synaptic Vesicle Exocytosis Positive Regulation Of Vasculogenesis	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane
Pathways		Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation ARMS-mediated activation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling MAP2K and MAPK activation Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF MET activates RAP1 and RAC1 Signaling downstream of RAS mutants	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
Drugs			Sorafenib XL281 N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) ( 31374203) Crohn's disease ( 30500874) High altitude adaptation ( 28373541) Osteoporosis-related phenotypes ( 20548944)	anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 28869590)
Interacting Genes		43 interacting genes: AFDN APBB1IP ARHGEF1 BIN1 BMX BRAF ELOA FADD FAF1 FAS GABARAPL2 GANAB HDAC1 HSPA1A HSPA4 KRIT1 MTNR1A NTRK1 PDE6D PPP2R1A PRKACA RABAC1 RAF1 RALGDS RAP1GAP RAP1GDS1 RAPGEF1 RAPGEF2 RAPGEF3 RAPGEF4 RAPGEF5 RAPGEF6 RASA1 RASA3 RASGRP2 RASGRP4 RASIP1 RGL4 RGS14 RUNDC3A SMARCA2 SMARCA4 TNFRSF10C	39 interacting genes: AKT1 ARAF AURKA BAD CCDC88A HRAS ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MRAS NANOG OIP5 PAK2 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ
Entrez ID		5906	673
HPRD ID		01545	01264
Ensembl ID		ENSG00000116473	ENSG00000157764
Uniprot IDs		A8KAH9 P62834	A0A2R8Y8E0 P15056
PDB IDs		1C1Y 1GUA 3KUC 4KVG	1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?